Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Bullish +75

Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates

AI-generated analysis

📈 Charles River Laboratories reported Q1 earnings of $2.06 per share, beating the consensus estimate of $1.96.

📉 Adjusted quarterly earnings of $2.34 compare to a year-ago figure of $2.34, with the beat driven by non-recurring items adjustments.

🎯 The company delivered an earnings surprise of +5.24% in the current quarter and has surpassed EPS estimates four times over the last four quarters.

💰 Revenue for the quarter ended March 2026 reached $995.83 million, surpassing the consensus estimate by 2.55%.

📊 Charles River has topped revenue estimates for four consecutive quarters, with year-over-year revenue growth of roughly 1.2%.

📉 Shares have underperformed the S&P 500 significantly in 2026 so far, losing about 8.9% versus a 7.6% market gain.

🔮 The company currently holds a Zacks Rank #3 (Hold), indicating expectations that shares will perform in line with the near future.

🏥 Charles River operates within the Medical Services industry, which is ranked in the top 37% among all tracked industries.

🤖 Management commentary on the earnings call will be crucial for determining the sustainability of recent price movements.

👀 Analysts expect consensus EPS to reach $2.68 and revenues of $1 billion for the coming quarter based on current estimates.

🔍 Earnings estimate revisions are a key indicator tracking stock performance, with Zacks research highlighting their strong correlation.

💼 Competitor Sonida Senior Living is scheduled to report results on May 11 with an expected quarterly loss of $1.67 per share.

📈 Sonida expects revenues of $87.94 million for the upcoming quarter, representing a 9.5% increase from the year-ago period.

🛑 Investors are advised to monitor industry-level trends as they can materially impact Charles River's stock performance.

Bullish Signals
  • Charles River Laboratories reported earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.96 per share by +5.24%.
  • The company posted revenues of $995.83 million for the quarter ended March 2026, surpassing the consensus estimate by 2.55% and representing growth compared to the year-ago revenue of $984.17 million.
  • Charles River has surpassed consensus EPS estimates four times over the last four quarters, demonstrating consistent performance above expectations.
  • The company is part of the Medical Services industry, which currently ranks in the top 37% of Zacks industries and historically outperforms by a factor of more than 2 to 1.
  • Over the long run, Charles River shares have gained about 48% over the last year, demonstrating strong long-term resilience despite recent short-term fluctuations.
Risk Factors
  • Charles River Laboratories shares have lost approximately 8.9% year-to-date, significantly underperforming the S&P 500's gain of 7.6%.
  • Ahead of the earnings release, estimate revisions for Charles River were mixed, resulting in a Zacks Rank #3 (Hold) which suggests the stock is expected to merely perform in line with the market rather than outperform.
  • Earnings per share of $2.06 represent a decline from $2.34 per share recorded in the same quarter one year ago.
  • The industry context presents uncertainty, as peer company Sonida Senior Living (SNDA) is expected to report a quarterly loss of $1.67 per share representing a -116.9% year-over-year deterioration.
Full Analysis
Charles River Laboratories International, Inc. (CRL) reported quarterly earnings of $2.06 per share for the quarter ended March 2026, surpassing the Zacks Consensus Estimate of $1.96 by 5.24%. This compares to adjusted earnings of $2.34 per share in the same quarter a year ago. Revenues reached $995.83 million, exceeding estimates by 2.55%, marking the fourth consecutive quarter where both EPS and revenue beat consensus. However, current consensus EPS for the coming quarter is estimated at $2.68 on $1 billion in revenues, while the fiscal year consensus stands at $10.97 on $3.97 billion in revenues. Despite the strong recent performance, CRL shares have underperformed the broader market over the past year, dropping about 8.9% versus an S&P 500 gain of 7.6%. The article notes that the stock's immediate future performance is largely dependent on management commentary and upcoming estimates revisions. Based on mixed estimate revisions ahead of the report, the company currently holds a Zacks Rank #3 (Hold), suggesting shares are expected to perform in line with the market. The industry outlook is positive, with the Medical Services sector ranked in the top 37% out of 250+ industries, which historically correlates with significant outperformance compared to the bottom half of industries. The text also briefly mentions a peer company, Sonida Senior Living (SNDA), noting that it has not yet released results for the quarter ended March 2026 but is expected to report on May 11 with an anticipated loss of $1.67 per share and revenues of $87.94 million, up 9.5% year-over-year.